The Prospective Randomized Trial Evaluating the Efficacy of the Mitomycin C and Cisplatin Regimen (MP) versus Standard First-Line Chemotherapy in Patients With Advanced BRCA1 2-Associated Ovarian Cancer (NCT04747717). Вопр. онкол. 2022, 68 (5), 628-638. https://doi.org/10.37469/0507-3758-2022-68-5-628-638.